Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone

Journal of Bone and Mineral Research

Volumn 26, Issue 3, 2011, Pages 512-518

  Merlotti, Daniela ^a   Rendina, Domenico ^b   Gennari, Luigi ^a   Mossetti, Giuseppe ^b   Gianfrancesco, Fernando ^c   Martini, Giuseppe ^a   De Filippo, Gianpaolo ^b   Avanzati, Annalisa ^a   Franci, Beatrice ^a   Campagna, Maria Stella ^a   Strazzullo, Pasquale ^b   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

bisphosphonates; intramuscular regimen; intravenous regimen; neridronate; Paget disease of bone

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; NERIDRONIC ACID; VITAMIN D;

ACUTE PHASE RESPONSE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; OSTEOARTHRITIS; PAGET BONE DISEASE; SIDE EFFECT; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

AGED; ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; MALE; OSTEITIS DEFORMANS; PAIN; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 79951829302     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.237     Document Type: Article

References (32)

1. Paget J,. On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans. 1877; 60: 37-63.
2. Altman RD,. Paget disease of bone. In:, Coe FL, Favus MJ, eds. Disorders of Bone and Mineral Metabolism. New York: Raven Press, 1991; 1027-1064.
3. Cooper C, Harvey NC, Dennison EM, van Staa TP,. Update on the epidemiology of Paget disease of bone. J Bone Miner Res. 2006; 21: P3-8.
4. van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C,. Incidence and natural history of Paget disease of bone in England and Wales. J Bone Miner Res. 2002; 17: 465-471. (Pubitemid 34171761)
5. Gold DT, Boisture J, Shipp KM, Pieper CF, Lyles KW,. Paget's disease of bone and quality of life. J Bone Miner Res. 1996; 11: 1897-1904. (Pubitemid 26425682)
6. Selby PL, Davie MWJ, Ralston SH, Stone MD,. Guidelines on the management of Paget's disease of bone. Bone. 2002; 31: 10-19.
7. Merlotti D, Gennari L, Martini G, Nuti R,. Current options for the treatment of Paget's disease of the bone. Open Access Rheumatology Research and Reviews. 2009; 1: 107-120.
8. Gennari L, Merlotti D, Mossetti G, et al. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone. Mini Rev Med Chem. 2009; 9: 1052-1063.
9. Papapoulos SE, Eekhoff EM, Zwinderman AH,. Acquired Resistance to Bisphosphonates in Paget's Disease of Bone. J Bone Miner Res. 2006; 21: P88-P91.
10. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001; 296: 235-242. (Pubitemid 32112446)
11. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38: 617-627.
12. Papapoulos SE,. Bisphosphonate actions: physical chemistry revisited. Bone. 2006; 38: 613-616.
13. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81: 1013-1022. (Pubitemid 44175011)
14. Walsh JP, Attewell R, Stuckey BGA, et al. Treatment of Paget disease of bone: A survey of clinical practice in Australia. Bone. 2008; 42: 1219-1225.
15. Merlotti D, Gennari L, Martini G, et al. Comparison of Different Intravenous Bisphosphonate Regimens for Paget Disease of Bone. J Bone Miner Res. 2007; 22: 1510-1517. (Pubitemid 351229321)
16. Tong D, Gillick L, Hendrickson FR,. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982; 50: 893-899. (Pubitemid 12047122)
17. Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V,. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. Calcif Tissue Int. 2004; 75: 189-196. (Pubitemid 39331647)
18. Gutteridge DH, Ward LC, Stewart GO, et al. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res. 1999; 14: 79-84. (Pubitemid 29455804)
19. Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ,. Effect of multiple intravenous pamidronate courses in Paget disease of bone. Rev Rhum (Engl Ed). 1999; 66: 467-476. (Pubitemid 29500793)
20. Atkins RM, Yates AJ, Gray RE, et al. Aminohexane bisphosphonate in the treatment of Paget disease of bone. J Bone Miner Res. 1987; 2: 273-2799.
21. Delmas P, Chapuy MC, Edouard C, Meunier PJ,. Beneficial effects of aminohexane bisphosphonate in patients with Paget disease of bone resistant to sodium etidronate. Am J Med. 1987; 83: 276-282.
22. Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio F,. Paget disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate. Bone. 1998; 23: 543-548. (Pubitemid 28529459)
23. Fleisch H,. Bisphosphonates: mechanism of action. Endocrine Rev. 1998; 19: 80-100.
24. Neves M, Gano L, Pereira N, et al. Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nuclear Medicine and Biology. 2002; 29: 329-338. (Pubitemid 34258555)
25. Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with Neridronate in Paget disease. Clin Exp Rheumatol. 2002; 20: 55-58. (Pubitemid 34213733)
26. Adami S, Gatti D, Bertoldo F, et al. Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcif Tissue Int. 2008; 83: 301-307.
27. Bertoldo F, Pancheri S, Zenari S, et al. Serum 25(OH)D levels modulate the acute phase response associated to the first nitrogen containing bisphosphonate infusion. J Bone Miner Res. 2010; 25: 447-454.
28. Chen L, Cencioni MT, Angelini DF, Borsellino G, Battistini L, Brosnan CF,. Transcriptional profiling of gamma-delta T cells identifies a role for vitamin D in the immunoregulation of the Vgamma9Vdelta2 response to phosphonate-containing ligands. J Immunol. 2005; 174: 6144-6152. (Pubitemid 40663804)
29. Deane A, Constancio L, Fogelman I, Hampson G,. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord. 2007; 8: 3.
30. Geller JL, Hu B, Reed S, Mirocha J, Adams JS,. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. Endocr Pract. 2008; 14: 293-297.
31. Barone A, Giusti A, Pioli G, et al. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc. 2007; 55: 752-757. (Pubitemid 46668979)
32. Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009; 20: 239-244.